Shares Magazine
9.25p+0.00 (+0.00%)17 Apr 2025, 17:15
Jump to:
Ondine Biomedical Inc. Fundamentals
| Company Name | Ondine Biomedical Inc. | Last Updated | 2025-04-17 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 443.233 m | Market Cap | £41.00 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -0.07 CAD | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.0872 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | 211.8421 | Cash Equity Ratio | 64.1053 |
| Quick Ratio | 0.3635 | Current Ratio | 0.80 |
| Price To Book Value | 3,333.3333 | ROCE | 0 |
Ondine Biomedical Inc. Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Ondine Biomedical Inc. Company Financials
| Assets | 2023 | 2022 |
|---|---|---|
| Tangible Assets | 949,000.00 CAD | 1.40 m CAD |
| Intangible Assets | 0 | 0 |
| Investments | 0 | 0 |
| Total Fixed Assets | 984,000.00 CAD | 1.44 m CAD |
| Stocks | 1.07 m CAD | 1.29 m CAD |
| Debtors | 326,000.00 CAD | 182,000.00 CAD |
| Cash & Equivalents | 2.98 m CAD | 13.13 m CAD |
| Other Assets | 0 | 0 |
| Total Assets | 5.73 m CAD | 16.57 m CAD |
| Liabilities | 2023 | 2022 |
|---|---|---|
| Creditors within 1 year | 3.49 m CAD | 3.91 m CAD |
| Creditors after 1 year | 159,000.00 CAD | 1.02 m CAD |
| Other Liabilities | 0 | 0 |
| Total Liabilities | 3.65 m CAD | 4.92 m CAD |
| Net assets | 2.08 m CAD | 11.64 m CAD |
| Equity | 2023 | 2022 |
|---|---|---|
| Called up share capital | 239.65 m CAD | 235.04 m CAD |
| Share Premium | 0 | 0 |
| Profit / Loss | -14.41 m CAD | -19.37 m CAD |
| Other Equity | 2.08 m CAD | 11.64 m CAD |
| Preference & Minorities | 0 | 0 |
| Total Capital Employed | 2.08 m CAD | 11.64 m CAD |
| Ratios | 2023 | 2022 |
|---|---|---|
| Debt Ratio | 0.07 CAD | 0.04 CAD |
| Debt-to-Equity | 0.08 CAD | 0.05 CAD |
| Assets / Equity | 211.8421 | 211.8421 |
| Cash / Equity | 64.1053 | 64.1053 |
| EPS | -0.07 CAD | -0.09 CAD |
| Cash Flow | 2023 | 2022 |
|---|---|---|
| Cash from operating activities | -13.65 m CAD | -16.34 m CAD |
| Cashflow before financing | -9.87 m CAD | -16.62 m CAD |
| Increase in Cash | -10.04 m CAD | -16.93 m CAD |
| Income | 2023 | 2022 |
|---|---|---|
| Turnover | 1.20 m CAD | 638,000.00 CAD |
| Cost of sales | 500,000.00 CAD | 351,000.00 CAD |
| Gross Profit | 703,000.00 CAD | 287,000.00 CAD |
| Operating Profit | -14.80 m CAD | -18.76 m CAD |
| Pre-Tax profit | -14.41 m CAD | -19.37 m CAD |
Ondine Biomedical Inc. Company Background
| Sector | Healthcare |
|---|---|
| Activities | Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportableoperating segment that is antimicrobial photodynamic therapy (aPDT) products. |
| Latest Interim Date | 30 Sep 2024 |
| Latest Fiscal Year End Date | 7 Jun 2024 |
Ondine Biomedical Inc. Directors
| Appointed | Name | Position |
|---|---|---|
| 2024-05-03 | Mr. Craig A. Tooman | Non-Executive Director |
| 2025-02-04 | Ms. Carolyn Cross | Executive Director,Chief Executive Officer |
| 2011-09-06 | Mr. Colin D. Watt | Executive Director |
| 2025-02-26 | Dr. Nicholas Loebel | President and Chief Technology Officer |
| 2011-09-06 | Mr. Michael Crane | Executive Director |
| 2011-09-06 | Mr. Terry M. Holland | Executive Director |
| 2025-01-31 | Ms. Margaret Shaw | Non-Executive Director |
| 2010-12-21 | Dr. Merrill Biel | Executive Director |
| 2011-08-09 | Mr. Pierre Leduc | Executive Director,Chairman |
| 2025-01-29 | Dr. Junaid Bajwa | Non-Executive Director |
| 2025-01-29 | Mr. Jean Charest | Non-Executive Director,Chairman |
| 2025-01-29 | Ms. Jean Duvall | Non-Executive Director,Senior Independent Non-Executive Director |
| 2025-03-28 | Mr. Michael Farrar | Non-Executive Director |
| 2024-06-27 | Dr. Simon Sinclair | Non-Executive Director |
Ondine Biomedical Inc. Contact Details
| Company Name | Ondine Biomedical Inc |
|---|---|
| Address | 1100 Melville Street, Suite 888, Vancouver, V6E4A6 |
| Telephone | +1 604 669-0555 |
| Website | https://www.ondinebio.com |
Ondine Biomedical Inc. Advisors
| Auditor | Ernst & Young LLP |
|---|
| Auditor | Ernst & Young Ltd. |
|---|
| Auditor | Davidson & Company LLP |
|---|---|
| Phone | +1 604 687-0947 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Dunelm Group PLC | 1,074.00 | 13.29 |
| Asos PLC | 313.50 | 6.63 |
| Rentokil Initial PLC | 350.00 | 5.01 |
| Sainsbury (J) PLC | 256.80 | 3.55 |
| Dr. Martens PLC | 52.80 | 3.53 |
| Pershing Square Holdings LTD | 3,414.00 | 3.45 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Dowlais Group PLC | 51.40 | -6.03 |
| Fresnillo PLC | 1,021.00 | -5.55 |
| Jupiter Fund Management PLC | 69.30 | -5.07 |
| Goodwin PLC | 6,780.00 | -4.51 |
| Spectris PLC | 1,987.00 | -4.38 |
| Twentyfour Income Fund Limited | 108.60 | -3.89 |
Risers/fallers data from previous trading day. Today's data available from 8:15am.